Promising pancreatic cancer drug trial pulled before it even started
NCT ID NCT07026916
First seen Nov 17, 2025 · Last updated May 21, 2026 · Updated 21 times
Summary
This study was designed to test a new drug called GFH375 in people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.